Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2017 financial results on Tuesday, May 2, 2017 , before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Year Ended 2016 Financial Results
- Vertex Pharmaceuticals to Acquire Cystic Fibrosis Candidate, CTP-656, from Concert Pharmaceuticals for up to $250 Million - - CTP-543 On Track to Advance Into Phase 2a Trial - - Conference Call Scheduled Today at 8:30 a.m. EST - LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
- Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF - - Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments - - Concert to Host Conference Call at 8:30 AM EST to
View HTML
Toggle Summary Concert Pharmaceuticals Presents CTP-543 Phase 1 Results at American Academy of Dermatology Annual Meeting
- Program on Track to Begin Phase 2a Trial in the First Quarter of 2017 - LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that the results from the Company's Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers
View HTML
Toggle Summary Concert Pharmaceuticals to Report Full Year 2016 Results on March 6, 2017, and Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2016 , on Monday, March 6, 2017 , before the U.S. financial markets open. The Company will host a conference call and webcast
View HTML
Toggle Summary Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for CTP-656, Concert's next generation CFTR potentiator being developed for the treatment of cystic fibrosis.
View HTML
Toggle Summary Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe
Company to Host Conference Call and Webcast Today, January 17, 2017 at 8:30 A.M. ET LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today provided further details on the development plan in the U.S. and Europe for CTP-656, a next generation CFTR potentiator being
View HTML
Toggle Summary Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today announced the initiation of a U.S. -based Phase 2 clinical trial evaluating CTP-656 (deuterated ivacaftor), a next generation CFTR potentiator being developed for the treatment of cystic fibrosis.
View HTML
Toggle Summary Concert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results
CTP-543 to Advance into Phase 2 in First Quarter of 2017 LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today announced the Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers has been completed.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. ( NASDAQ : CNCE) today reported financial results for the third quarter of 2016. "As we approach the end of the year, our team continues to make progress in advancing the drug
View HTML